These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 23030234)

  • 21. Carvedilol inhibits the cardiostimulant and thermogenic effects of MDMA in humans: Lost in translation.
    Hysek CM; Schmid Y; Rickli A; Liechti ME
    Br J Pharmacol; 2013 Nov; 170(6):1273-5. PubMed ID: 24033079
    [No Abstract]   [Full Text] [Related]  

  • 22. Contribution of cytochrome P450 2D6 to 3,4-methylenedioxymethamphetamine disposition in humans: use of paroxetine as a metabolic inhibitor probe.
    Segura M; Farré M; Pichini S; Peiró AM; Roset PN; Ramírez A; Ortuño J; Pacifici R; Zuccaro P; Segura J; de la Torre R
    Clin Pharmacokinet; 2005; 44(6):649-60. PubMed ID: 15910012
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacological characterization of ecstasy synthesis byproducts with recombinant human monoamine transporters.
    Pifl C; Nagy G; Berényi S; Kattinger A; Reither H; Antus S
    J Pharmacol Exp Ther; 2005 Jul; 314(1):346-54. PubMed ID: 15831439
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition.
    de la Torre R; Farré M; Roset PN; Pizarro N; Abanades S; Segura M; Segura J; Camí J
    Ther Drug Monit; 2004 Apr; 26(2):137-44. PubMed ID: 15228154
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MDMA induced dopamine release in vivo: role of endogenous serotonin.
    Koch S; Galloway MP
    J Neural Transm (Vienna); 1997; 104(2-3):135-46. PubMed ID: 9203077
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effects of fluoxetine on the subjective and physiological effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans.
    Tancer M; Johanson CE
    Psychopharmacology (Berl); 2007 Jan; 189(4):565-73. PubMed ID: 17047932
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of fluoxetine on carvedilol pharmacokinetics, CYP2D6 activity, and autonomic balance in heart failure patients.
    Graff DW; Williamson KM; Pieper JA; Carson SW; Adams KF; Cascio WE; Patterson JH
    J Clin Pharmacol; 2001 Jan; 41(1):97-106. PubMed ID: 11225566
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ecstasy use and serotonin syndrome: a neglected danger to adolescents and young adults prescribed selective serotonin reuptake inhibitors.
    Dobry Y; Rice T; Sher L
    Int J Adolesc Med Health; 2013; 25(3):193-9. PubMed ID: 24006318
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The hyperthermic and neurotoxic effects of 'Ecstasy' (MDMA) and 3,4 methylenedioxyamphetamine (MDA) in the Dark Agouti (DA) rat, a model of the CYP2D6 poor metabolizer phenotype.
    Colado MI; Williams JL; Green AR
    Br J Pharmacol; 1995 Aug; 115(7):1281-9. PubMed ID: 7582557
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serotonin reuptake transporter deficiency modulates the acute thermoregulatory and locomotor activity response to 3,4-(±)-methylenedioxymethamphetamine, and attenuates depletions in serotonin levels in SERT-KO rats.
    Lizarraga LE; Phan AV; Cholanians AB; Herndon JM; Lau SS; Monks TJ
    Toxicol Sci; 2014 Jun; 139(2):421-31. PubMed ID: 24595820
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CYP2D6 function moderates the pharmacokinetics and pharmacodynamics of 3,4-methylene-dioxymethamphetamine in a controlled study in healthy individuals.
    Schmid Y; Vizeli P; Hysek CM; Prestin K; Meyer Zu Schwabedissen HE; Liechti ME
    Pharmacogenet Genomics; 2016 Aug; 26(8):397-401. PubMed ID: 27253829
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Repeated exposure to MDMA provides neuroprotection against subsequent MDMA-induced serotonin depletion in brain.
    Bhide NS; Lipton JW; Cunningham JI; Yamamoto BK; Gudelsky GA
    Brain Res; 2009 Aug; 1286():32-41. PubMed ID: 19555677
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sustained recreational use of ecstasy is associated with altered pre and postsynaptic markers of serotonin transmission in neocortical areas: a PET study with [¹¹C]DASB and [¹¹C]MDL 100907.
    Urban NB; Girgis RR; Talbot PS; Kegeles LS; Xu X; Frankle WG; Hart CL; Slifstein M; Abi-Dargham A; Laruelle M
    Neuropsychopharmacology; 2012 May; 37(6):1465-73. PubMed ID: 22353758
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of GBR 12909 and fluoxetine on the acute and long term changes induced by MDMA ('ecstasy') on the 5-HT and dopamine concentrations in mouse brain.
    O'Shea E; Esteban B; Camarero J; Green AR; Colado MI
    Neuropharmacology; 2001; 40(1):65-74. PubMed ID: 11077072
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MDMA-induced impairment in primates: antagonism by a selective norepinephrine or serotonin, but not by a dopamine/norepinephrine transport inhibitor.
    Verrico CD; Lynch L; Fahey MA; Fryer AK; Miller GM; Madras BK
    J Psychopharmacol; 2008 Mar; 22(2):187-202. PubMed ID: 18308800
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serotonin (1A) receptor involvement in acute 3,4-methylenedioxymethamphetamine (MDMA) facilitation of social interaction in the rat.
    Morley KC; Arnold JC; McGregor IS
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Jun; 29(5):648-57. PubMed ID: 15908091
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risperidone attenuates and reverses hyperthermia induced by 3,4-methylenedioxymethamphetamine (MDMA) in rats.
    Shioda K; Nisijima K; Yoshino T; Kuboshima K; Iwamura T; Yui K; Kato S
    Neurotoxicology; 2008 Nov; 29(6):1030-6. PubMed ID: 18722468
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The neuropharmacology of prolactin secretion elicited by 3,4-methylenedioxymethamphetamine ("ecstasy"): a concurrent microdialysis and plasma analysis study.
    Murnane KS; Kimmel HL; Rice KC; Howell LL
    Horm Behav; 2012 Feb; 61(2):181-90. PubMed ID: 22197270
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vivo imaging of cerebral serotonin transporter and serotonin(2A) receptor binding in 3,4-methylenedioxymethamphetamine (MDMA or "ecstasy") and hallucinogen users.
    Erritzoe D; Frokjaer VG; Holst KK; Christoffersen M; Johansen SS; Svarer C; Madsen J; Rasmussen PM; Ramsøy T; Jernigan TL; Knudsen GM
    Arch Gen Psychiatry; 2011 Jun; 68(6):562-76. PubMed ID: 21646575
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Repeated doses administration of MDMA in humans: pharmacological effects and pharmacokinetics.
    Farré M; de la Torre R; Mathúna BO; Roset PN; Peiró AM; Torrens M; Ortuño J; Pujadas M; Camí J
    Psychopharmacology (Berl); 2004 May; 173(3-4):364-75. PubMed ID: 15071716
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.